Navigation Links
New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors
Date:10/29/2009

kly became the preferred method of breast cancer detection. Not until 2004 was the first non-surgical procedure looking towards breast cancer detection using Positron Emission Tomography (PET) with 18fluorodeoxyglucose (FDG) approved for use in patients. FDG-PET has two significant drawbacks: 1) FDG-PET leaves a frustrating 30% of tumors undetected; and 2) FDG cannot reliably distinguish between benign and malignant tumors.

The significant advance of NVB-64 is the recognition of genetic changes at the cellular level, as a genomic biomarker, rather than the overly generalized metabolic markers found with FDG.

Nearly as important as the human implications are the enormous financial ramifications. Lead investigator Mathew Thakur Ph.D. Professor of Radiology and Director of the Laboratories of Radiopharmaceutical Research and Molecular Imaging at Thomas Jefferson University Hospital says, "The use of NVB64-PET scan in the future may minimize the need for unnecessary biopsy of benign tumors." Currently, nearly 6 million such biopsies are performed annually in the United States, at an estimated annual cost of $30 billion. Approximately 80% or 4.8 million biopsies, demonstrate benign pathology.

The biomarkers NuView has in development can, with alteration of the radionuclide attached to the compound, change them from a diagnostic to a targeted therapy, or a pairing of a target specific diagnostic and therapy. NuView Medical Director Peter S. Conti, MD, PhD adds, "Development of targeted diagnostics that can be modified to also carry therapeutic isotopes can lead to unique agents that can broaden the range of therapies available for cancer patients."

Anticipated Benefits of NVB-64:

  • Same day, immediate confirmation of the patient having either benign or malignant breast tumor(s).
  • Choice of care in selecting a screening method to determine the malignant or benign status of a mass found on a mammogram.'/>"/>

SOURCE NuView Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
2. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
3. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
4. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
5. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
6. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
9. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... EAST HANOVER, N.J., June 1, 2011 Novartis Pharmaceuticals ... its current oncology products and investigational agents at the ... Oncology (ASCO). These data underscore the company,s commitment to ... cancer. "Through our commitment to R&D and ...
... Actavis, an international generic pharmaceutical company, today announced that ... Administration to market Donepezil Hydrochloride Tablets a generic equivalent of ... Tablets 5mg and 10mg had US total sales of approximately ... according to IMS Health.     About ...
Cached Medicine Technology:Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 2Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 3Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 4Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 5Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 6Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 7Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 8Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 9Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 10Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 11Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 12Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 13Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 14Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 15Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 16Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 17Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 18Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S. 2
(Date:4/17/2014)... of Canadians surveyed said they would participate in public ... of genetic conditions, only 80 per cent said they ... sequence their newborns, genomes.,Most newborns in North America have ... two of life in which a tiny amount of ... about five to 54 conditions, depending on the state ...
(Date:4/17/2014)... Johnston, whose work has transformed cancer care in Northern ... European Academy of Cancer Sciences., The Academy, which was ... highly distinguished oncologists and cancer researchers which aims to ... Europe. , Professor Johnston, whose leadership has seen cancer ... of the UK league table to near the top, ...
(Date:4/17/2014)... more research to be carried out into HIV ... In a paper in The Lancet Infectious ... colleagues in the department of Parasitology and researchers ... University of Cambridge and the Royal Veterinary College ... of HIV/AIDS and schistosomiasis of children, and found ...
(Date:4/16/2014)... PHOENIX, Ariz. April 15, 2014 The Translational ... philanthropists at their annual Founders Dinner for their support ... The event took place March 28 in Scottsdale. , ... Catherine Ivy Foundation, received TGen,s John S. McCain Leadership ...
(Date:4/16/2014)... A team that includes scientists from the School of Medicine ... Antonio, Johns Hopkins University and St. Mary,s University reported the ... infect the body. , The fungal pathogen Candida albicans ... is the most common fungal pathogen to infect humans. It ...
Breaking Medicine News(10 mins):Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... illness as college grads, study finds , , WEDNESDAY, May 6 ... the worst health, a new study finds. , Almost ... in less than very good health, and levels of health ... released Wednesday by the Robert Wood Johnson Foundation Commission to ...
... Lower Risk of Fractures WASHINGTON, May 6 Of ... families, one of the most important is health knowledge, ... the National Osteoporosis Foundation. A Gift from Mothers ... Osteoporosis Awareness and Prevention Month, which is attempting to ...
... May 6 Endo Pharmaceuticals (Nasdaq: ENDP ) ... America and Merrill Lynch 2009 Health Care Conference on Wednesday, ... Holveck, President and Chief Executive Officer of Endo, will review ... live and can be accessed from Endo,s website at ...
... May 6 /PRNewswire-Asia/ -- China Medicine Corporation,(OTC ... Company"), a developer,and a leading distributor of ... medicines (TCM), nutritional and dietary supplements, and,medical ... it will conduct,a conference call at 9:00 ...
... Net service revenues increased 77% to $69.2 million- Visiting ... million- Net income increased 118% to $5.6 million- Diluted ... more shares outstandingLOUISVILLE, Ky., May 6 Almost Family, ... provider of home health nursing services, announced today its ...
... catch high percentage of skin cancers at Women,s Dermatologic ... As champions of sun safety and skin health, ... (WDS) provided free skin cancer screenings and education ... SC recently. In a busy day of outreach, local ...
Cached Medicine News:Health News:Less Education May Mean Poorer Health 2Health News:Less Education May Mean Poorer Health 3Health News:Mothers Play a Powerful Role in Determining Strength of Daughters' Bones 2Health News:Mothers Play a Powerful Role in Determining Strength of Daughters' Bones 3Health News:Mothers Play a Powerful Role in Determining Strength of Daughters' Bones 4Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 3Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 4Health News:China Medicine Announces Conference Call to Discuss First Quarter 2009 Results 2Health News:Almost Family Reports First Quarter 2009 Results 2Health News:Almost Family Reports First Quarter 2009 Results 3Health News:Almost Family Reports First Quarter 2009 Results 4Health News:Almost Family Reports First Quarter 2009 Results 5Health News:Almost Family Reports First Quarter 2009 Results 6Health News:Almost Family Reports First Quarter 2009 Results 7Health News:Almost Family Reports First Quarter 2009 Results 8Health News:Almost Family Reports First Quarter 2009 Results 9Health News:Almost Family Reports First Quarter 2009 Results 10Health News:Almost Family Reports First Quarter 2009 Results 11Health News:Almost Family Reports First Quarter 2009 Results 12Health News:Almost Family Reports First Quarter 2009 Results 13Health News:Almost Family Reports First Quarter 2009 Results 14Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 2Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 3
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
NS2000 Bipolar Generator provides precise coagulation without tissue sticking....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: